INFEX Therapeutics

Biotechnology
Growth Investment
2017

Based at Alderley Park, INFEX Therapeutics aims to tackle the urgent global threat from antimicrobial resistance, which left untreated, will kill an extra 10m patients per year – more deaths than cancer.  It helps accelerate the development of new antibiotics by providing development services to companies around the world in return for a commercial share from new products developed.

In 2020 it expanded its portfolio to tackle a wider array of infectious diseases, developing lifesaving antibacterial and antiviral therapies.

Anti-microbial resistance is now recognised as a threat to humanity and INFEX is a key part of the UK’s response to this global threat. INFEX is a founder partner of CARB-X, a US-based anti-microbial grant funder which is investing $455m into suitable projects around the world. The costs of its unique development capabilities are significantly reduced thanks to CARB-X grants, while the scientific risks are reduced through access to the CARB-X panel of world leading experts.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Dr David Whitcombe

view complete team

Contact us

Alderley Park
Alderley Edge
Cheshire
SK10 4TG

Tel: 01625 344300

email